Clinical trials: Gastrointestinal Infection
Liver Fibrosis, Cirrhosis
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis
The purpose of this research study is to test the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) injected subcutaneously (under the skin) for the treatment of advanced liver fibrosis and cirrhosis in patients with…
- Trial name
- NCT00043303
- Testing
- interferon gamma-1b
- Volunteers
- 502 people
- Sponsor
- InterMune
Chronic Hepatitis B
A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses.
- Trial name
- NCT05717686
- Testing
- AHB-137 injection
- Where
- 9 sites in United States, Hong Kong and 2 more
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AusperBio Therapeutics Inc.
Cystic Fibrosis
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF2 (NCT00104520)
- Testing
- AZLI 75 mg two times a day (BID)/three times a day (TID)
- Where
- 56 sites in United States
- Volunteers
- 211 people
- Sponsor
- Gilead Sciences
Cystic Fibrosis
Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection
The purpose of this study is to evaluate the safety and efficacy of 2 dose combinations of fosfomycin/tobramycin for inhalation (FTI), following a 28-day course of Aztreonam for Inhalation (AZLI) in patients with cystic fibrosis…
- Trial name
- NCT00794586
- Testing
- FTI, AZLI
- Where
- 36 sites in United States
- Volunteers
- 120 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Hepatitis C, Chronic
A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
PPI-668 is an antiviral agent (a hepatitis C NS5A inhibitor) that is being developed as a potential treatment for hepatitis C virus infection.
- Trial name
- NCT01448200
- Testing
- PPI-668
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Presidio Pharmaceuticals, Inc.
Chronic Hepatitis C
Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.
- Trial name
- NCT00591214
- Testing
- MP-424 (Telaprevir)
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis B
A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)
The purpose of this study is to demonstrate the durability of protection against hepatitis B virus (HBV) infection approximately 8-9 years after vaccination with Vaxelis®.
- Trial name
- NCT04490499
- Testing
- HBVAXPRO™
- Where
- 10 sites in Finland
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Hepatitis B, Chronic
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
This study is being done to compare the safety and efficacy of PEG-Intron™ to that of PEGASYS™ in participants with chronic hepatitis B (hepatitis B envelope antigen [HBeAg] positive or negative) who have not previously been…
- Trial name
- NCT01641926
- Testing
- PEG-Intron™, PEGASYS™
- Volunteers
- 402 people
- Sponsor
- Merck Sharp & Dohme LLC
HBV
Access HBV Assays - European Union (EU) Clinical Trial Protocol -
The objective of this protocol is the collection and testing of clinical samples to determine the clinical performance of the Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer.
- Trial name
- NCT04904835
- Testing
- Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
- Where
- 5 sites in France
- Volunteers
- 21,210 people
- Sponsor
- Beckman Coulter, Inc.
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).
The effects of treatment with different doses of PEGASYS in combination with different doses of ribavirin will be evaluated in patients with CHC genotype 1 who have a high viral titer, body weight greater than 85kg (187lbs) and…
- Trial name
- NCT00077649
- Testing
- ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)
The goal of this study was to compare hepatic pharmacokinetics (PK) derived from liver tissue to plasma PK after administration of grazoprevir (MK-5172) to participants with chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT01537900
- Testing
- Grazoprevir
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B
This study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis B.
- Trial name
- NCT00128544
- Testing
- telbivudine, valtorcitabine
- Where
- 3 sites in Hong Kong, New Zealand and 1 more
- Volunteers
- 130 people
- Sponsor
- Novartis
Hepatitis C
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
The purpose of this study is to follow-up with participants from feeder studies who achieved sustained virologic response (SVR) over 24 hours posttreatment (SVR24), to assess durability of SVR, and to assess the changes in liver…
- Trial name
- NCT02753699
- Testing
- Alisporivir
- Where
- 119 sites in United States, Argentina and 20 more
- Volunteers
- 723 people
- Sponsor
- Debiopharm International SA
Appendicitis
A Trial to Assess the Efficacy and Safety of Morinidazole in Patients With Appendicitis
To assess the efficacy, safety, tissue distribution of target organ and Population Pharmacokinetic (PPK) of morinidazole and sodium chloride injection with surgery in patients with suppurative or gangrenous appendicitis
- Trial name
- NCT03380793
- Testing
- morinidazole
- Where
- China
- Volunteers
- 614 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Chronic Hepatitis C (CHC)
Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation
This study seeks to assess the effectiveness of Glecaprevir plus Pibrentasvir in participants with chronic hepatitis C in a real-life setting across clinical practice populations in the Russian Federation.
- Trial name
- EVEREST (NCT03868163)
- Where
- 9 sites in Russia
- Volunteers
- 161 people
- Sponsor
- AbbVie
Chronic Hepatitis B
Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E
The purpose of this study is to examine the immunogenicity and efficacy of HBsAg Vaccine in combination with Entecavir in patients who have been treated with HB110E HBV DNA vaccine.
- Trial name
- NCT01813487
- Testing
- HBsAg vaccine with Entecavir
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Genexine, Inc.
Hepatitis C, Chronic
A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.
The purpose of this study is to determine whether a 10-day course of therapy with orally administered VCH-759 given at 400-mg, 600-mg or 800-mg three times daily can effectively reduce the amount of circulating virus (i.e., viral…
- Trial name
- NCT00389298
- Testing
- VCH-759 (BCH-27759)
- Where
- 4 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.